TickerSpark Feed

drug manufacturers general

Everything tagged "drug manufacturers general" across the TickerSpark archives.

AbbVie (ABBV): Growth Momentum vs. Valuation Risk

AbbVie is delivering strong growth from Skyrizi, Rinvoq and neuroscience, but a rich valuation and heavy debt keep the stock in Hold territory.

Nov 10, 2026·20 MIN

Healthcare Drug Manufacturers - General Healthcare

Research ReportGILD

Gilead Sciences (GILD): HIV Strength Powers Growth, But Valuation Limits Upside

Gilead posted strong HIV-led growth, with base business sales up 16% and management raising full-year guidance. The stock still looks fairly valued near consensus, keeping the call at Hold.

Nov 3, 2026·21 MIN

Healthcare Drug Manufacturers - General Healthcare

Research ReportAZN

AstraZeneca (AZN): Oncology Growth Supports a Buy

AstraZeneca earns a Buy as oncology and rare disease offset BioPharmaceuticals pressure. The stock looks reasonably valued with strong cash flow and a clear growth mix shift.

Oct 31, 2026·20 MIN

Healthcare Drug Manufacturers - General Healthcare

Research ReportMRK

Merck & Company (MRK): KEYTRUDA Growth vs. Patent Risk

Merck is a Buy as KEYTRUDA still drives growth, WINREVAIR is scaling fast, and the pipeline offers a path through the 2028 patent transition. The stock remains a transition story, but new products and late-stage oncology assets support the case.

Oct 30, 2026·19 MIN

Healthcare Drug Manufacturers - General Healthcare

Research ReportLLY

Eli Lilly (LLY): Obesity Growth Power Meets Premium Valuation

Eli Lilly is delivering exceptional growth from Mounjaro and Zepbound, but the stock already reflects a premium multiple and heavy concentration in its obesity franchise.

Oct 30, 2026·18 MIN

Healthcare Drug Manufacturers - General Pharmaceuticals

Earnings AnalysisBMY

Bristol-Myers Squibb Company (BMY) Gains After Deep Q3 Earnings

Bristol-Myers Squibb Company (BMY) gains after a deep Q3 earnings review showing beats on EPS and revenue, stronger growth-brand sales, and raised revenue guidance. The analysis also weighs margin pressure, lower EPS guidance, and the ongoing shift away from legacy products.

Oct 29, 2026·7 MIN

Healthcare Drug Manufacturers - General

Research ReportBMY

Bristol-Myers Squibb (BMY): Cash Flow and Growth Portfolio Support

Bristol-Myers Squibb combines strong cash generation with a broadening growth portfolio, but legacy-product dependence and debt keep the story balanced. The stock looks attractive on valuation, with Eliquis and newer launches helping offset patent pressure.

Oct 29, 2026·19 MIN

Healthcare Drug Manufacturers - General Pharmaceuticals

Earnings FlashBMY

Bristol-Myers Squibb Company (BMY) slips despite earnings beats

Bristol-Myers Squibb Company (BMY) slips 0.6% even after posting earnings beats, as investors weigh the latest results against broader market sentiment.

Oct 29, 2026·2 MIN

Healthcare Drug Manufacturers - General

Research ReportBIIB

Biogen (BIIB): Growth Portfolio Turnaround Gains Traction

Biogen’s growth portfolio now exceeds its legacy MS franchise, driven by SPINRAZA, LEQEMBI, SYFOVRE, and EMPAVELI. The stock looks improved, but execution risk and leverage keep the rating at Hold.

Oct 15, 2026·21 MIN

Healthcare Drug Manufacturers - General Biotech

Research ReportJNJ

Johnson & Johnson (JNJ): Growth Broadens Beyond STELARA

Johnson & Johnson is a Buy as newer medicines and MedTech growth offset STELARA’s decline. The stock looks fairly valued to slightly attractive with strong cash generation and a broad pipeline.

Oct 13, 2026·18 MIN

Healthcare Drug Manufacturers - General Healthcare

Research ReportNVO

Novo Nordisk (NVO): GLP-1 Growth Meets Price Pressure

Novo Nordisk still has a powerful obesity and diabetes franchise, but slower growth, pricing pressure, and tougher competition have shifted the stock into a Hold case. Wegovy momentum and strong profitability support the thesis, while valuation is now close to fair value.